ARIAD perspective...(from CNA Finance)
How The Market Reacted To The News
As investors, one of the first lessons that we learn is that the news moves the market. Any time positive news is released with regard to a publicly traded company, we can expect to see gains in the value of the stock. In this case, the news released with regard to ARIA was overwhelmingly positive. Not only did the company beat expectations in the second quarter, we're seeing strong product growth and a clear plan for success. As a result, the stock is climbing in the market. Currently (12:14), the stock is trading at $9.31 per share after a gain of $0.89 per share or 10.57% thus far today.
What We Can Expect To See Moving Forward
Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from ARIA stock. At the end of the day, the company's earnings report told us quite a bit. First and foremost, Iclusig is doing incredibly well. During the quarter, the company brought in $65.3 million in sales on the drug. That's more than double the revenue from the treatment in the same quarter one year ago and shows that sales are just under $100 million for the first half of 2016. So, growth in that area is overwhelmingly promising. On top of that, I'm incredibly excited with regard to the company's pipeline and plans for the future. All in all, Ariad Pharmaceuticals stock looks like it's going to climb from here.
